Phase 3 Antibody-mediated Rejection Clinical Trials
2 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–2 of 2 trials
Recruiting
Phase 3
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)
Antibody-mediated Rejection
Biogen120 enrolled59 locationsNCT06685757
Recruiting
Phase 3
TocIlizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients
Antibody-mediated Rejection
Vastra Gotaland Region50 enrolled8 locationsNCT04561986